{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:41:53Z","timestamp":1784346113676,"version":"3.55.0"},"reference-count":52,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T00:00:00Z","timestamp":1712016000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Advanced Nursing"],"published-print":{"date-parts":[[2024,11]]},"abstract":"Abstract<\/jats:title>\n \n Aims<\/jats:title>\n To explore healthcare professionals' perceptions and experiences of take\u2010home naloxone initiatives in acute care settings to gain an understanding of issues facilitating or impeding dispensing.<\/jats:p>\n <\/jats:sec>\n \n Design<\/jats:title>\n Systematic literature review.<\/jats:p>\n <\/jats:sec>\n \n Data Sources<\/jats:title>\n Cochrane, MEDLINE and CINAHL were searched from 15\/03\/2021 to 18\/03\/2021, with a follow\u2010up search performed via PubMed on 22\/03\/2021. The years 2011 to 2021 were included in the search.<\/jats:p>\n <\/jats:sec>\n \n Review Methods<\/jats:title>\n A systematic literature review focused on qualitative studies and quantitative survey designs. Synthesis without meta\u2010analysis was undertaken using a thematic analysis approach.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Seven articles from the United States of America (5), Australia (1) and Canada (1) with 750 participants were included in the review. Results indicate ongoing stigma towards people who use drugs with preconceived moral concerns regarding take\u2010home naloxone. There was confusion regarding roles and responsibilities in take\u2010home naloxone dispensing and patient education. Similarly, there was a lack of clarity over logistical and financial issues.<\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Take\u2010home naloxone is a vital harm reduction initiative. However, barriers exist that prevent the optimum implementation of these initiatives.<\/jats:p>\n <\/jats:sec>\n \n Impact<\/jats:title>\n \n What is already known:\n \n \n Deaths due to opioid overdose are a global health concern, with take\u2010home naloxone emerging as a key harm reduction scheme.<\/jats:p>\n <\/jats:list-item>\n \n Globally, less than 10% of people who use drugs have access to treatment initiatives, including take\u2010home naloxone.<\/jats:p>\n <\/jats:list-item>\n \n An optimum point of distribution of take\u2010home naloxone is post\u2010acute hospital care.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n \n What this paper adds:\n \n \n There is role confusion regarding responsibility for the provision of take\u2010home naloxone and patient education. This is exacerbated by inconsistent provision of training and education for healthcare professionals.<\/jats:p>\n <\/jats:list-item>\n \n Logistical or financial concerns are common and moral issues are prevalent with some healthcare professionals questioning the ethics of providing take\u2010home naloxone.<\/jats:p>\n <\/jats:list-item>\n \n Stigma towards people who use drugs remains evident in some acute care areas which may impact the use of this intervention.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n \n Implications for practice\/policy:\n \n \n Further primary research should examine what training and education methods are effective in improving the distribution of take\u2010home naloxone in acute care.<\/jats:p>\n <\/jats:list-item>\n \n Education should focus on reduction of stigma towards people who use drugs to improve the distribution of take\u2010home naloxone.<\/jats:p>\n <\/jats:list-item>\n \n Standardized care guidelines may ensure interventions are offered equally and take\u2010home naloxone \u2018champions\u2019 could drive initiatives forward, with support from harm reduction specialists.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Reporting Method<\/jats:title>\n This has adhered to the PRISMA reporting guidelines for systematic reviews.<\/jats:p>\n <\/jats:sec>\n \n Patient or Public Contribution<\/jats:title>\n No patient or public contribution.<\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/jan.16181","type":"journal-article","created":{"date-parts":[[2024,4,2]],"date-time":"2024-04-02T11:29:22Z","timestamp":1712057362000},"page":"4361-4371","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A systematic review exploring healthcare professionals' perceptions of take\u2010home naloxone dispensing in acute care areas"],"prefix":"10.1111","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9294-6658","authenticated-orcid":false,"given":"Karen","family":"Osinski","sequence":"first","affiliation":[{"name":"National Poisons Information Service NHS Lothian Edinburgh Napier University Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janyne","family":"Afseth","sequence":"additional","affiliation":[{"name":"Edinburgh Napier University Robert Gordon University Aberdeen UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,4,2]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Advisory Council on the Misuse of Drugs. (2023).ACDM review of the UK naloxone implementation.https:\/\/www.gov.uk\/government\/publications\/acmd\u2010naloxone\u2010review\/acmd\u2010review\u2010of\u2010the\u2010uk\u2010naloxone\u2010implementation\u2010accessible"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2019.11.019"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cptl.2018.11.007"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajem.2018.03.036"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.26099\/r689\u2010fk36"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2018.06.005"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11524\u2010006\u20109120\u2010z"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.01.037"},{"issue":"1","key":"e_1_2_10_10_1","first-page":"45","article-title":"Developing a framework for critiquing health research","volume":"6","author":"Caldwell K.","year":"2005","journal-title":"Journal of Health, Social and Environmental Issues"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13104\u2010016\u20102268\u2010z"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11673-016-9720-6"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.14608"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2020.02.013"},{"key":"e_1_2_10_15_1","volume-title":"Drug\u2010related deaths and mortality in Europe: update from the EMCDDA expert network","author":"European Monitoring Centre for Drugs and Drug Addiction","year":"2021"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.socscimed.2020.113470"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2016.05.013"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.12894"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13643-017-0454-2"},{"key":"e_1_2_10_20_1","volume-title":"National naloxone programme Scotland: monitoring report 2017\/18","author":"Information Services Division","year":"2018"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2017.03.008"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1017\/cem.2018.368"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1017\/cem.2017.390"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2017.07.014"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12982"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13326"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.04.012"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.1040493.1"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00599-4"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/NUR.0000000000000515"},{"key":"e_1_2_10_31_1","volume-title":"Drug\u2010related deaths in Scotland in 2019","author":"National Records of Scotland","year":"2020"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913\u2010019\u20104469\u20103"},{"issue":"3","key":"e_1_2_10_33_1","first-page":"10","article-title":"Opioid abuse and overdose crisis: New treatment available\u2014Controversy continues between harm\u2010reduction treatment and abstinence treatment","volume":"12","author":"Oyemade A.","year":"2015","journal-title":"Innovations in Clinical Neuroscience."},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-137-28127-2"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/PHH.0000000000000668"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365\u20102524.2006.00683.x"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jen.2020.05.006"},{"key":"e_1_2_10_38_1","volume-title":"Opioids, cocaine, cannabis and other illicit drugs","author":"Ritchie H.","year":"2022"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16081"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25351"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2021.02.004"},{"key":"e_1_2_10_42_1","volume-title":"Service evaluation of Scotland's national take\u2010home naloxone programme","author":"Scottish Government","year":"2014"},{"key":"e_1_2_10_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265\u2010019\u201001154\u20105"},{"key":"e_1_2_10_44_1","unstructured":"The Human Medicines (Amendment) Regulations. (2015).https:\/\/www.legislation.gov.uk\/nisr\/2015\/178\/contents\/made\u00a9Crown and database right."},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.1080\/1750984X.2021.1952471"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.02.018"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209282"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annemergmed.2019.04.020"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2016.1142921"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1616348"},{"key":"e_1_2_10_51_1","volume-title":"Opioid overdose","author":"World Health Organisation","year":"2023"},{"key":"e_1_2_10_52_1","first-page":"33","volume-title":"Non\u2010fatal opioid overdose and associated health outcomes: Final summary report","author":"Zibbell J.","year":"2019"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp170759"}],"container-title":["Journal of Advanced Nursing"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jan.16181","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jan.16181","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jan.16181","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T09:39:49Z","timestamp":1771234789000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jan.16181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,2]]},"references-count":52,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1111\/jan.16181"],"URL":"https:\/\/doi.org\/10.1111\/jan.16181","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1111\/JAN.16181\/v2\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JAN.16181\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JAN.16181\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JAN.16181\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JAN.16181\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JAN.16181\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JAN.16181\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JAN.16181\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1111\/JAN.16181\/v2\/review1","asserted-by":"object"}]},"ISSN":["0309-2402","1365-2648"],"issn-type":[{"value":"0309-2402","type":"print"},{"value":"1365-2648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,2]]},"assertion":[{"value":"2023-08-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}